Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
reports
Marker Therapeutics (MRKR) Stock Price & Analysis
462 Followers
MRKR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.67 - $6.60
Previous Close$1.28
Volume41.94K
Average Volume (3M)141.33K
Market Cap
$11.26M
Enterprise Value$12.35M
Total Cash (Recent Filing)$6.40M
Total Debt (Recent Filing)$7.49M
Price to Earnings (P/E)-0.4
Beta0.79
Next Earnings
Aug 10, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.96
Shares Outstanding8,798,829
10 Day Avg. Volume28,991
30 Day Avg. Volume141,328
Standard Deviation0.27
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.97
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Marker Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRKR FAQ
What was Marker Therapeutics Inc’s price range in the past 12 months?
Marker Therapeutics Inc lowest stock price was $0.67 and its highest was $6.60 in the past 12 months.
What is Marker Therapeutics Inc’s market cap?
Currently, no data Available
When is Marker Therapeutics Inc’s upcoming earnings report date?
Marker Therapeutics Inc’s upcoming earnings report date is Aug 10, 2023 which is in 74 days.
How were Marker Therapeutics Inc’s earnings last quarter?
Marker Therapeutics Inc released its earnings results on May 11, 2023. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.8 by $0.23.
Is Marker Therapeutics Inc overvalued?
According to Wall Street analysts Marker Therapeutics Inc’s price is currently Overvalued.
Does Marker Therapeutics Inc pay dividends?
Marker Therapeutics Inc does not currently pay dividends.
What is Marker Therapeutics Inc’s EPS estimate?
Marker Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marker Therapeutics Inc have?
Marker Therapeutics Inc has 8,798,829 shares outstanding.
What happened to Marker Therapeutics Inc’s price movement after its last earnings report?
Marker Therapeutics Inc reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.8. Following the earnings report the stock price went down -7.042%.
Which hedge fund is a major shareholder of Marker Therapeutics Inc?
Among the largest hedge funds holding Marker Therapeutics Inc’s share is Aisling Capital Management LP. It holds Marker Therapeutics Inc’s shares valued at 1M.
---
Marker Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 682.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.33%
12-Months-Change
Fundamentals
Return on Equity
-96.82%
Trailing 12-Months
Asset Growth
-49.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Marker Therapeutics Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
---
Top 5 ETFs holding MRKR
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold MRKR. The ETFs are listed according to market value of MRKR within the ETF
---
CASI Pharmaceuticals
―
Spruce Biosciences
―
Codiak BioSciences
―
Inhibitor Therapeutics
―
---